Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Second IVF company to be floated sees share prices grow

30 June 2014

By Ayesha Ahmad

Appeared in BioNews 760

An Australian fertility company has seen the price of its shares rise on the first day of its public listing on the stock market.

Shares in the Monash IVF Group rose 6.5 percent after opening at AU$1.96, meaning the country's second largest IVF company grew by almost AU$13 million in value in one day on its debut to the market.

The company is the second public listing from the Australian fertility sector in the last year to enter the stock market and follows the public listing of Virtus, the world's first listed fertility company.

Monash IVF boasts three of the top fertility specialists and hosts clinics in the Australian states of Victoria, South Australia and the Northern Territory. The company provides genetic testing and ultrasounds, as well fertility services, which make up the majority of its earnings.

Monash expanded to Malaysia in 2013 and has co-operative clinics in China. On Tuesday, chief executive, James Thiedeman, told Business Day: 'Our focus will remain on building our footprint in Malaysia and looking to expand our service across the broader Association of Southeast Asian Nations region'.

Other health related companies are following suit. Pacific Equity Partners listed hygiene products company Asaleo Care Ltd on Friday and has so far raised AU$656 million in shares. Reuters explains there is opportunity for investors to benefit from the growing demand of a health system in Australia that is heavily subsidised by the state.

SOURCES & REFERENCES
The West Australian | 26 June 2014
 
Reuters | 25 June 2014
 
The Australian | 26 June 2014
 
Sydney Morning Herald | 26 June 2014
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

29 August 2017 - by Shaoni Bhattacharya 
Treatment costs for IVF may be coming down in Australia as a result of a price war between fertility clinics...
21 November 2016 - by Rikita Patel 
A number of Australian IVF clinics are potentially misleading patients about their success rates, a consumer watchdog has warned...

23 June 2014 - by Dr Anna Cauldwell 
Two patients with the serious inherited blood disorder beta-thalassemia have been able to stop blood transfusions 12 days after receiving experimental gene therapy...
17 March 2014 - by Patricia Cassidy 
Myriad Genetics has failed to obtain a preliminary injunction to prevent a competitor, Ambry Genetics, from offering BRCA-related genetic testing products...
17 June 2013 - by Jessica Ware 
The first IVF business to be listed on the stock market enjoyed a buoyant first day of trading on the Australian exchange. Shares in Virtus Health closed 8.5 percent above their starting price, which was already set at the top end of an indicative range...
31 January 2012 - by Ruth Saunders 
Swiss pharmaceutical company Roche has made an unsolicited bid worth $5.7 billion to takeover US DNA sequencing firm Illumina....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation